Citigroup’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Citigroup’s Portfolio ARIA Stock Details ARIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-36,600	Closed	-$455K	–	7517
2016 Q4	$455K	Buy	36,600 +2,600	+8%	+$31.3K	﹤0.01%	4473
2016 Q3	$465K	Sell	34,000 -11,700	-26%	-$117K	﹤0.01%	3956
2016 Q2	$338K	Buy	45,700 +12,100	+36%	+$90.8K	﹤0.01%	4033
2016 Q1	$215K	Sell	33,600 -1,400	-4%	-$7.85K	﹤0.01%	5017
2015 Q4	$219K	Sell	35,000 -150,300	-81%	-$986K	﹤0.01%	4665
2015 Q3	$1.08M	Buy	185,300 +14,700	+9%	+$113K	﹤0.01%	2998
2015 Q2	$1.41M	Buy	+170,600	New	+$1.51M	﹤0.01%	2861

Other funds holding ARIA

FPF

FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

Citigroup's ARIA Position: Q1 2017 in Review

Citigroup sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 777,786 shares — an estimated $9.68M sold.

Citigroup first reported a position in ARIA in Q2 2013 and held it in 15 quarters. The position peaked at $9.68M in Q4 2016. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.

Citigroup reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
Citigroup sold 777,786 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $9.68M.
Citigroup first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
Citigroup's Ariad Pharmaceuticals Inc position peaked at $9.68M in Q4 2016.
1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.

Based on Citigroup's 13F filing for Q1 2017, filed 12 May 2017.